经皮胫后神经刺激治疗帕金森病神经源性下尿路症状的24个月持续疗效:临床与尿动力学结果
本研究评估经皮胫后神经刺激(PTNS)对帕金森病伴逼尿肌活动患者的24个月持续疗效。76例患者接受12周诱导治疗后,按14天、21天、28天间隔逐渐延长方案维持至24个月。结果显示排尿日记、生活质量问卷及多项尿动力学参数显著改善,但最大尿流率(Qmax)无显著变化。
要点
- PTNS递减方案治疗24个月可显著改善帕金森病患者的排尿症状和生活质量。
- 尿动力学指标(首次逼尿肌不自主收缩容量、最大膀胱测压容量等)显著改善,但Qmax无变化。
- 该方案耐受性良好,支持PTNS作为帕金森病神经源性下尿路症状的长期治疗选择。
核心结论
- PTNS递减方案治疗24个月可显著改善帕金森病伴逼尿肌活动患者的排尿症状及尿动力学参数。
研究设计与样本
- 前瞻性研究,共纳入76例帕金森病伴逼尿肌活动的患者,其中男性44例(57.9%),女性32例(42.1%)。
- 12周治疗后,PTNS按14天间隔治疗3个月,21天间隔3个月,28天间隔至24个月。
主要发现
- 与基线相比,24个月时白天排尿次数减少4.6次/日,急迫性尿失禁减少4.2次/日,急迫感发作减少6.2次/日,夜尿减少2.4次(P<.001)。
- 排尿量平均改善71.4 cc(P<.05)。
- 首次逼尿肌不自主收缩容量(1st IDCV)、最大膀胱测压容量(MCC)、首次逼尿肌不自主收缩最大逼尿肌压力(1st IDC Pdetmax)、MCC时最大逼尿肌压力(MCC Pdetmax)、最大尿流率时逼尿肌压力(PdetQmax)及残余尿量(PVR)在3、12、24个月均显著改善(各P<.001)。
- 最大尿流率(Qmax)无显著变化(P>.05)。
关键数值与推荐
- 疗效评估包括3天排尿日记及ICIQ-SF、OAB-V8、OAB-q SF问卷,于第3、6、9、12及24个月完成。
- 尿动力学参数在3、12、24个月评估,除Qmax外均较基线显著改善(P<.001)。
临床怎么用
- 对于帕金森病伴逼尿肌活动的神经源性下尿路症状患者,可考虑采用PTNS递减方案进行长期治疗。
- 治疗期间应定期评估排尿日记、生活质量问卷及尿动力学参数以监测疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the sustained therapeutic effect of percutaneous posterior tibial nerve stimulation (PTNS) treatment in Parkinson's disease patients with detrusor activity during 24 months. METHODS: After 12 weeks therapy, PTNS was applied at 14-day intervals for 3 months, 21-day intervals for 3 months and 28-day intervals through 24 months. The patients completed a 3-day voiding diary and ICIQ-SF, OAB-V8, OAB-q SF questionnaires at 3rd, 6th, 9th,12th and 24th month. RESULTS: A total of 76 patients were enrolled in the study. Of these 44 (57.9%) were men and 32 (42.1%) women. The differences of compared parameters at baseline and at the end of 24 months were as follows; daytime frequency decreased by 4.6 voids daily, urge incontinence decreased by 4.2 episodes daily, urgency episodes decreased by 6.2 episodes daily, nocturia decreased by 2.4 voids (P <.001) and voided volume improved by a mean of 71.4 cc (P <.05). When compared with baseline significant improvements were seen in the volume at the first involuntary detrusor contraction (1st IDCV), maximum cystometric capacity (MCC), maximal detrusor pressure at first involuntary detrusor contraction (1st IDC Pdetmax), maximal detrusor pressure at MCC (MCC Pdetmax), detrusor pressure at maximal flow (PdetQmax) and post-void residual volume (PVR) after PTNS treatment at 3, 12, 24 months (P <.001 for each) except maximal flow rate (Qmax) value (P ˃.05). CONCLUSIONS: These results have demonstrated the significant improvements both on voiding and urodynamic parameters under PTNS treatment with a tapering protocol for during 24-months in Parkinson's disease with detrusor activity.
引用
- Kabay S, Kabay SC. The Sustained Therapeutic Effects of Percutaneous Posterior Tibial Nerve Stimulation in the Treatment of Neurogenic Lower Urinary Tract Symptoms in Patients with Parkinson's Disease: 24-months Clinical and Urodynamic Results. Urology. 2021. PMID: 33561470. doi:10.1016/j.urology.2021.01.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。